CDC

Instructions:

REQUEST FOR DETERMINATION OF RESEARCH STATUS

To be completed by the staff member with lead responsibility for the project and approved by branch chief (if applicable) and Division ADS. A separate PGO funding memo is required if project is research and involves human subjects regardless of the CDC staff role.

- (1) Use this form to declare: (a) the research status of any project, (b) role or roles of CDC staff
 - (2) A short summary should be attached offering specific details about the project and the role of staff.
 - (3) Be sure to complete all applicable items, obtain appropriate signatures and submit this form for approval.

Tracking Number:

(Use PGO number if cooperative agreement, grant, etc.)

Date submitted: Title of Project:		10/27/2016						
		Formative assessment regarding contraception use in the U.S. Virgin Islands (USVI) in the context of Zika						
Dates for pro	oject peri	od:	Dates for fu	nding (if	applicable):			
Beginning	:	11/01/2016		Beginning:				
Ending:		02/01/2017		Ending:				
personnel,	vision, as role of C				tus, etc.		pe of pro	oject, funding restrictions,
[X] Nev [] Cor		n, without revision(e)		[]	Revision Continuation, with	revision	(s)
			s)		[]	Continuation, with	evision	(5)
Lead staff m	ember:		Contact info	rmation:		ase indicate your role		
Name:	Anna B	rittain	Division:	DRH	[X]	Project officer	[]	Technical monitor
User ID:	AVG8		Telephone:	770-488-55	[] 15	Principal investigator	[]	Investigator
Scientific	Ethics 1	umber:	- Mailstop:	F74	[]	Consultant	[]	Other (please explain)
If YES,	list those	activities which ar	e research:					
	CDC proj	ect research or pub	lic health prac	ctice (check	all that a	apply)?		
[]	Resear	ch		[X] Public health practice				
	Check a			C		that apply:		
		Human subjects in		[2		nergency Response	[]	Surveillance
	[]	Human subjects no	ot involved	[] Pr	ogram evaluation	[]	Other (please explain)
	EARCH i protecti		bjects, has the	project or 1	research	activities been review	ed by tl	ne CDC IRB for human
a. []	NO, New	project, not yet re	viewed	d. [] YES	, Reviewed and appro	oved by	CDC
b. []	NO, Exis	ting project, not re	ady to submit]	lf YES, please list pro	tocol nu	umber <u>and</u>
c. []	NO, Sub	mitted for approva	l			expiration date		
				e. [RESEARCH, no CD iired)	C invest	tigators (CDC IRB not
				f. [] N/A	(Not Applicable)		
If RESE	EARCH,	ist any other CDC	staff involved	in this proj	ect, pleas	e include the name, r	ole, and	scientific ethics number

Tracking NO. <u>No Funding</u>

Name				Role (project officer, investigator, consultant, etc.)					Scientific ethics number Prin
	Anı	na Britt	ain						
				CARCH PRO ns 4-6, OTHI					CH (as identified in 45CFR46.101),
4.			-	sed research			•		
[]	YES		If YES, this	s research	cannot b	e exempt	ed and must be reviewed	by an IRB (skip to question 7).
[]	NO							
		ne prop apply)?		arch involve	fetuses, pr	egnant w	vomen, o	r human in vitro fertiliza	tion as targets (such that Subpart B
[]	YES		If YES, th question 7		h canno	ot be exe	mpted and must be rev	viewed by an IRB (skip to
[]	NO							
<u>Educa</u>	tional	l Resea	<u>rch</u>						
6	.1	norma	l educatio	onal practice	s (e.g., res	earch on	regular a	and special education stra	ngs, AND does the research involve ategies or research on the assroom management methods)?
		[]	YES		[]	NO			
	rch In	volving	Surveys.	, Interview P	rocedures	(includin	ng Focus	groups), Observation of	Public Behavior, or Educational
<u>Tests</u> 6	.2						ve, diagn	ostic, aptitude, achievem	ent), survey procedures, interview
		[]	YES	bservation o		NO		If NO skip 6.3	
				18 years of a			biects?	n no sap 0.5	
		[]	YES	•	•		•	ted and must be reviewed	d by an IRB (skip to item 7)
		[]	NO						
		6.2.1						nanner that human subje iked to the subjects;	ects can be identified <u>directly or</u>
			[]	YES		[]	NO		
		6.2.2	place the employa subjects	e subjects at Ibility or rep ' (or relative	risk of crin utation? (I s' or associ	minal or Examples iates') po	civil liab s here ma ssible su	ility, or be damaging to t ay include: the collection	rch setting have the potential to he subjects' financial standing, of sensitive data regarding the criminal history or intent, medical formation).
			[]	YES		[]	NO		
6	.3								ent), survey procedures, interview ler paragraph 6.2 of this section:
		[]	YES		[]	NO		If NO skip to 6.4	
		6.3.1	Will this public of	ffice?	volve hum	an subjee		re elected or appointed p	ublic officials or candidates for
			[]	YES		[]	NO		
		6.3.2	informa	tion will be 1 1 only in the	naintained	through	out the r	esearch and thereafter?	f the personally identifiable (Note: CDC can use this exemption s been obtained to cover the
_			[]	YES	_	[]	NO		
	0			licly Availab			-		
6	.4	diagno	stic speci		isting' mea	ans existi		e the study begins)?	nts, records, pathological or
		[]	YES		[]	NO		If NO skip to 7	
		6.4.1		aterial or in YES	iormation		available	e:	
			[]	169		[]	INU		

Form 684R_NR (revised January 2003)

[]

6.4.2 Is this material or information recorded in such a manner by the investigator that the subjects cannot be identified directly or indirectly through identifiers linked to the subjects?

(Note: If a link is created by an investigator even temporarily, for research purposes, this criterion is not met. If a temporary link is created by clinical staff who already have access to the data, this criterion is met).

- [] YES (there are no identifying information and no unique identifiers or codes)YES
 - NO (there are identifiers (including codes))
- 7. Please prepare and attach a short summary paragraph (<1 page); if this is new:
 - a. Be sure to include the purpose of the project, specific details about the project and the role of the CDC staff member(s) in the project. In explaining one's role as a consultant be particularly careful to identify involvement in things like: study design decisions, oversight of protocol development, participation in review of data collection procedures, and particpation in data analysis and/or manuscript preparation, as well as whether there will be access to identifiable or personal data.
 - b. Explain your project status selection (research--non-exempt, exempt, no CDC investigator or not involving human subjects; public health practice). If you selected research not involving human subjects be sure to indicate if the data includes any personal information (e.g., name, SSN), linkable study identification numbers or codes, or geographical information.

Increasing access to contraception among women who choose to delay pregnancy in USVI is a primary strategy to reduce Zikarelated adverse outcomes. There are an estimated 21,000 USVI women of reproductive age (WRA), approximately 12,000 of whom are at risk of unintended pregnancy. There is an urgent need for effective messaging about contraception and contraceptive access. DESIGN: CDC staff will conduct 6 focus groups with USVI women and men(18-44 years) to assess knowledge, attitudes, and beliefs regarding contraception use and access within the USVI. CDC staff will also assess preferred communication channels for receiving messages. Each group will be a maximum size of 12. We propose to conduct 5 focus groups with WRA that are stratified by age(i.e., 18-24 years vs. 25-44 years). We will conduct 1 focus group with men (not stratified by age) because of the important role they play in decisions about contraceptive use. DATA COLLECTION: Trained CDC project team members will conduct focus groups in-person using semi-structured focus group guide developed by the project team. Before the focus group, each participant will receive an informed consent form, including the purpose, as well as benefits and risks of participation. The guide and the consent form will be reviewed by partners in the USVI to ensure that they are culturally appropriate. Each focus group is expected to last from 90 to 120 minutes. A note taker will be present to observe the focus groups and capture salient points discussed, as well non-verbal cues within the group. In addition, the focus groups will be audio-recorded. DATA ANALYSIS: CDC team members will analyze the data manually and/or using a qualitative software package. A thematic analysis approach will be used to determine common themes related to the categories addressed in the discussion guides. Codes will be developed based on themes and applied to the text, and the data will be synthesized. All information collected will be held in confidence to the extent allowed by law. All individuals involved in data collection will receive ethics training as well as training concerning procedures and practices to ensure privacy of data. No personal identifying information will be collected during the focus groups or maintained in any data files. No data will be collected other than what is collected during the focus groups. All audio-recordings will be destroyed after notes have been verified. CDC will summarize the information for use in developing messaging specific to contraception as part of emergency response. If a description of focus group findings is published, data will be reported in aggregate and will not include information that may be used identify respondents directly or indirectly. This activity is public health practice as the data will identify, characterize, and solve an immediate health problem and the knowledge gained will directly benefit only those communities of focus group participants.

8. Please list the primary project site and all collaborating site(s).

	Site Name	Site Location	Assurance Number (FWA, MPA or SPA) if applicable
Primary Site	Community based organization,, e.g. Women's Coalition of St. Croix	St. Croix	

Explanation of project components:

9. If project involves research that is funded extramurally, list amount of award that should be restricted pending IRB approval and describe which project components will be affected, if known:

Approvals (signature and position title)	Date	Research Determination / Remarks
Anna Brittain - HEALTH COMMUNICATIONS SPECIALIST	10/27/2016	 [X] Public health practice [] Research not involving human subjects [] Research involving human subjects, no CDC investigators [] Research involving human subjects, CDC investigators, exempt [] Research involving human subjects, CDC investigators, not exempt [] Research involving human subjects, CDC investigators, not exempt [] Local IRB [] CDC Exemption [] CDC IRB
staff member completing this form		<u>Comments:</u> Thank you for your review! -Anna
Lee Warner - RESEARCH SCIENCE OFFICER	10/27/2016	 [X] Public health practice [] Research not involving human subjects [] Research involving human subjects, no CDC investigators [] Research involving human subjects, CDC investigators, exempt [] Research involving human subjects, CDC investigators, not exempt [] Research involving human subjects, CDC investigators, not exempt [] Local IRB [] CDC Exemption [] CDC IRB
Team Lead		<u>Comments:</u> hi shanna, per discussion yesterday here is the RD form for the USVI for Zika for the EOC. thanks in advance for your help
Shanna Cox - Associate Director for Science	10/29/2016	 [X] Public health practice [] Research not involving human subjects [] Research involving human subjects, no CDC investigators [] Research involving human subjects, CDC investigators, exempt [] Research involving human subjects, CDC investigators, not exempt (check if applicable) [] Local IRB [] CDC Exemption [] CDC IRB
Division ADS		<u>Comments:</u>
Joan Redmond Leonard - PUBLIC HEALTH ANALYST	10/31/2016	 [X] Public health practice [] Research not involving human subjects [] Research involving human subjects, no CDC investigators [] Research involving human subjects, CDC investigators, exempt [] Research involving human subjects, CDC investigators, not exempt [] Research involving human subjects, CDC investigators, not exempt [] Local IRB [] CDC Exemption [] CDC IRB
CUC ADS, Deputy ADS, or Human Subjects Contact		<u>Comments:</u>